Ratio Therapeutics

Ratio Therapeutics

Pharmaceuticals, 77 Sleeper St, Boston, , 2127, Massachusetts, United States, 11-50 Employees

ratiotx.com

  • twitter
  • LinkedIn

Who is RATIO THERAPEUTICS

A discovery through early clinical phase pharmaceutical company, Ratio Therapeutics employs a suite of innovative technologies to develop best-in-class targeted radiotherapeutics for the ...

Read More

map
  • 77 Sleeper St, Boston, Massachusetts, 2127, United States Headquarters: 77 Sleeper St, Boston, Massachusetts, 2127, United States
  • 2021 Date Founded: 2021
  • 11-50 Employees: 11-50
  • dollar-icon Revenue: $250 Million to $500 Million
  • tech-icon Active Tech Stack: See technologies
  • Jack Hoppin CEO:   Jack Hoppin

industries-icon Industry: Pharmaceuticals

SIC SIC Code: 2834 | NAICS Code: 325412 | Show More

checked-icon Does something look wrong? Fix it. | View contact records from RATIO THERAPEUTICS

Ratio Therapeutics Org Chart and Mapping

Employees
signout-image
You are signed out

Sign in to CIENCE GO Data to uncover contact details

crown-icon Free credits every month

Frequently Asked Questions Regarding Ratio Therapeutics

Answer: Ratio Therapeutics's headquarters are located at 77 Sleeper St, Boston, , 2127, Massachusetts, United States

Answer: Ratio Therapeutics's official website is https://ratiotx.com

Answer: Ratio Therapeutics's revenue is $250 Million to $500 Million

Answer: Ratio Therapeutics's SIC: 2834

Answer: Ratio Therapeutics's NAICS: 325412

Answer: Ratio Therapeutics has 11-50 employees

Answer: Ratio Therapeutics is in Pharmaceuticals

Answer: Ratio Therapeutics contact info: Phone number: Website: https://ratiotx.com

Answer: A discovery through early clinical phase pharmaceutical company, Ratio Therapeutics employs a suite of innovative technologies to develop best-in-class targeted radiotherapeutics for the treatment of cancer. Ratio Therapeutics TrilliumTM targeting scaffold combines pharmacokinetic modulation with best-in-class chelation technology to create proprietary small molecule targeting agents to attack a broad array of cancer targets. Our compounds accommodate imaging and therapeutic radioisotopes, ie "theranostics". The tunable nature of our platform combined with small-scale imaging trials in patients results in accelerated, de-risked compound selection.

Answer:

Premium Sales Data for Prospecting

  • Sales data across over 200M records

  • Up-to-date records (less decayed data)

  • Accurate Email Lists (real-world tested)

  • Powerful search engine and intuitive interface

lock icon Get Full Access